Eli Lilly in big reshuffle: Sets up new units for neuroscience and immunology

The US-based pharmaceutical company has kicked off a big management reshuffle after a top-level decision ordered independent units for neuroscience and immunology, with the latter handling a potential launch of Alzheimer's drug donanemab.
Photo: Mike Blake/REUTERS / X00030
Photo: Mike Blake/REUTERS / X00030
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL FRANK CHRISTENSEN

Oncology and the larger Bio-Medicines division will be hit particularly hard now that Eli Lilly initiates a series of larger organizational changes.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading